🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
25/10/2021 251,10 253,10 246,80 249,60 +0,00% 2,51% 42.893
22/10/2021 254,20 255,30 249,60 249,60 -1,81% 2,24% 32.533
21/10/2021 253,70 256,20 251,70 254,20 -0,12% 1,77% 45.187
20/10/2021 254,80 262,80 253,40 254,50 -0,62% 3,69% 73.445
19/10/2021 253,90 259,20 252,40 256,10 +1,15% 2,68% 77.389
18/10/2021 254,50 255,20 249,70 253,20 -0,82% 2,16% 50.749
15/10/2021 255,90 257,20 252,20 255,30 -1,47% 1,95% 66.480
14/10/2021 257,50 259,30 254,80 259,10 +1,29% 1,75% 42.067
13/10/2021 254,60 258,10 253,90 255,80 +0,63% 1,65% 36.509
12/10/2021 253,50 258,10 252,60 254,20 -0,70% 2,17% 27.557
11/10/2021 255,00 256,90 250,80 256,00 +0,27% 2,39% 35.021
08/10/2021 261,60 262,20 255,10 255,30 -2,30% 2,71% 32.946
07/10/2021 258,90 262,30 256,90 261,30 +2,83% 2,09% 59.430
06/10/2021 255,10 255,60 249,00 254,10 -1,82% 2,59% 58.047
05/10/2021 256,60 261,20 256,50 258,80 +0,94% 1,83% 31.666
04/10/2021 261,70 261,70 255,10 256,40 -2,32% 2,52% 45.942
01/10/2021 257,60 263,00 255,90 262,50 +1,16% 2,76% 71.642
30/09/2021 256,70 260,40 254,60 259,50 +1,88% 2,26% 59.926
29/09/2021 255,60 258,50 254,70 254,70 -0,04% 1,49% 39.163
28/09/2021 261,20 261,20 253,60 254,80 -2,49% 2,91% 42.848
27/09/2021 264,60 265,60 258,70 261,30 -0,61% 2,61% 46.345
24/09/2021 270,40 271,90 261,60 262,90 -2,63% 3,81% 62.292
23/09/2021 270,00 275,20 268,00 270,00 +0,30% 2,67% 64.324
22/09/2021 269,40 270,70 264,30 269,20 +0,34% 2,38% 46.823
21/09/2021 261,00 269,20 261,00 268,30 -2,97% 3,14% 71.975
20/09/2021 277,00 281,80 275,00 276,50 -1,29% 2,45% 63.539
17/09/2021 276,40 283,10 276,00 280,10 +2,71% 2,57% 106.218
16/09/2021 271,80 274,40 269,50 272,70 +0,26% 1,80% 56.188
15/09/2021 276,30 277,10 270,50 272,00 -1,59% 2,39% 81.439
14/09/2021 274,90 278,60 273,90 276,40 +0,55% 1,71% 34.573